Research Analysts Issue Forecasts for NBIX Q2 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at HC Wainwright upped their Q2 2025 earnings estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.63 per share for the quarter, up from their previous forecast of $0.58. HC Wainwright currently has a "Buy" rating and a $168.00 target price on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.17 EPS, FY2026 earnings at $4.19 EPS and FY2029 earnings at $13.44 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same period last year, the business posted $1.20 earnings per share. The company's revenue was up 11.1% compared to the same quarter last year.

A number of other equities research analysts have also recently weighed in on the stock. Bank of America cut their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a report on Friday, February 7th. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Piper Sandler reiterated an "overweight" rating and set a $154.00 price objective (down previously from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. Guggenheim increased their target price on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Wedbush reaffirmed an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock traded down $1.81 during midday trading on Thursday, reaching $115.71. 1,319,681 shares of the company's stock traded hands, compared to its average volume of 1,115,471. The stock has a 50 day moving average of $106.23 and a 200-day moving average of $121.85. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98. The company has a market cap of $11.45 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26.

Neurocrine Biosciences declared that its Board of Directors has approved a stock repurchase program on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.

Insider Activity

In related news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the sale, the director now directly owns 37,491 shares in the company, valued at $4,131,508.20. The trade was a 44.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Julie Cooke sold 700 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the sale, the insider now directly owns 18,831 shares of the company's stock, valued at approximately $2,227,330.68. This represents a 3.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,907 shares of company stock worth $4,935,982. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $25,000. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after buying an additional 97 shares in the last quarter. Brooklyn Investment Group increased its holdings in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock worth $32,000 after buying an additional 115 shares during the last quarter. GeoWealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Neurocrine Biosciences during the 1st quarter worth about $34,000. Institutional investors and hedge funds own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.